The Scientist - Antimicrobial cross-resistance risk


Bacteria that evolve resistance to antimicrobial therapies may be able to evade natural immune peptides. However, bacteria can evolve resistance to AMPs under strong selective pressure in vitro.

In 2003, Graham Bell at McGill University and Pierre-Henri Gouyon at Université Paris-Sud published an article voicing another concern—that when cross-resistance evolved, as it surely would, bacteria might become resistant not only to AMPs adopted for therapeutic use, but also to endogenous human peptides.